Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MCAM



This biomarker is also known as:
  • melanoma adhesion molecule,
  • Melanoma cell adhesion molecule,
  • Cell surface glycoprotein P1H12,
  • melanoma cell adhesion molecule,
  • cell surface glycoprotein MUC18,
  • melanoma-associated antigen A32,
  • Melanoma-associated antigen MUC18,
  • melanoma-associated antigen MUC18,
  • Melanoma-associated antigen A32,
  • S-endo 1 endothelial-associated antigen,
  • cell surface glycoprotein P1H12,
  • CD146 antigen,
  • CD146,
  • MUC18,
  • Gicerin,

View in BioMuta


From UniProtKB/Swiss-Prot: Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration.


QA State: Curated
Type: Gene
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…

Head & neck, NOS


Phase: One
QA State: Curated


No additional data available.

Performance Comment

MCAM is one of eight genes on a panel of differentially methylated genes from normal and OSCC clinical samples from patients with heterogenous risk profiles chosen for further validation. The eight genes are: HOXA9, NID2, GATA4, KIF1A, EDNRB, MCAM, DCC, and CALCA.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.